13 research outputs found
Proceedings of the conference on the Apalachicola River drainage system, 23-24 April 1976 Gainesville, Florida
(Document has 177 pages.
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus
Abstract
Background
Chronic obstructive pulmonary disease (COPD) has been classically divided into blue bloaters and pink puffers. The utility of these clinical subtypes is unclear. However, the broader distinction between airway-predominant and emphysema-predominant COPD may be clinically relevant. The objective was to define clinical features of emphysema-predominant and non-emphysematous COPD patients.
Methods
Current and former smokers from the Genetic Epidemiology of COPD Study (COPDGene) had chest computed tomography (CT) scans with quantitative image analysis. Emphysema-predominant COPD was defined by low attenuation area at -950 Hounsfield Units (LAA-950) â„10%. Non-emphysematous COPD was defined by airflow obstruction with minimal to no emphysema (LAA-950â<â5%).
Results
Out of 4197 COPD subjects, 1687 were classified as emphysema-predominant and 1817 as non-emphysematous; 693 had LAA-950 between 5â10% and were not categorized. Subjects with emphysema-predominant COPD were older (65.6 vs 60.6Â years, pâ<â0.0001) with more severe COPD based on airflow obstruction (FEV1 44.5 vs 68.4%, pâ<â0.0001), greater exercise limitation (6-minute walk distance 1138 vs 1331Â ft, pâ<â0.0001) and reduced quality of life (St. Georgeâs Respiratory Questionnaire score 43 vs 31, pâ<â0.0001). Self-reported diabetes was more frequent in non-emphysematous COPD (OR 2.13, pâ<â0.001), which was also confirmed using a strict definition of diabetes based on medication use. The association between diabetes and non-emphysematous COPD was replicated in the ECLIPSE study.
Conclusions
Non-emphysematous COPD, defined by airflow obstruction with a paucity of emphysema on chest CT scan, is associated with an increased risk of diabetes. COPD patients without emphysema may warrant closer monitoring for diabetes, hypertension, and hyperlipidemia and vice versa.
Trial registration
Clinicaltrials.gov identifiers: COPDGene
NCT00608764
, ECLIPSE
NCT00292552
.http://deepblue.lib.umich.edu/bitstream/2027.42/109496/1/12890_2014_Article_599.pd
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Impaired erythropoiesis in the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS) has been linked to heterozygous deletion of RPS14, which encodes the ribosomal protein small subunit 14. We generated mice with conditional inactivation of Rps14 and demonstrated an erythroid differentiation defect that is dependent on the tumor suppressor protein p53 (encoded by Trp53 in mice) and is characterized by apoptosis at the transition from polychromatic to orthochromatic erythroblasts. This defect resulted in age-dependent progressive anemia, megakaryocyte dysplasia and loss of hematopoietic stem cell (HSC) quiescence. As assessed by quantitative proteomics, mutant erythroblasts expressed higher levels of proteins involved in innate immune signaling, notably the heterodimeric S100 calcium-binding proteins S100a8 and S100a9. S100a8âwhose expression was increased in mutant erythroblasts, monocytes and macrophagesâis functionally involved in the erythroid defect caused by the Rps14 deletion, as addition of recombinant S100a8 was sufficient to induce a differentiation defect in wild-type erythroid cells, and genetic inactivation of S100a8 expression rescued the erythroid differentiation defect of Rps14-haploinsufficient HSCs. Our data link Rps14 haploinsufficiency in del(5q) MDS to activation of the innate immune system and induction of S100A8-S100A9 expression, leading to a p53-dependent erythroid differentiation defect